Abstract 4254
Background
Nivolumab demonstrated superior overall survival (OS) in clinical trials compared to docetaxel in patients previously treated for squamous (Sq) and non-squamous (NSq) aNSCLC. The objective was to describe in French real-world setting the characteristics and outcomes of patients treated with nivolumab for aNSCLC according to histology.
Methods
Based on the National hospitals database (PMSI), we performed a retrospective cohort of all NSCLC patients (ICD code: C34*) initiating nivolumab in 2015-2016 and followed until Dec 2017. Information on patients’ baseline characteristics (demographics, comorbidities, treatment history) was retrieved for Sq and NSq patients, and time to treatment discontinuation (TTD) with nivolumab and OS were estimated with Kaplan-Meier methodology.
Results
The overall cohort included 10,452 patients. Among them, a majority (N = 5805; 56%) presented NSq histology. Compared to Sq patients (N = 4647), NSq patients were younger (61.9 vs. 66.1 years; p < 0.001) and less frequently men (64.3% vs 79.3%; p < 0.001). They had less comorbidities such as hypertension (15.8% vs 23.0%; p < 0.001), diabetes (6.7% vs 11.7%; p < 0.001) and COPD (8.8% vs 18.1%; p < 0.001). Cerebral metastases were more frequent in the NSq population (22.9% vs 10.1%; p < 0.001). Median time from NSCLC diagnosis to nivolumab initiation was longer in NSq patients (14.2 vs 10.5 months; p < 0.001), as well as median time from first systemic treatment to nivolumab initiation (12.0 vs 8.9 months; p < 0.001). Nivolumab TTD was comparable across histologies with a median treatment duration of 2.8 months (p = 0.556). Proportion of NSq and Sq patients treated were 27.8% vs 25.7% (p < 0.001) at 6-month and 14.6% vs 12.1% (p < 0.001) at 1-year, respectively. Median OS was higher in NSq patients (12.6 vs 10.6 months; p = 0.004). NSq and Sq patients OS rates were 51.1% vs 45.7% (p < 0.001) at 1-year and 29.3% vs 24.6% (p < 0.001) at 2-year, respectively.
Conclusions
This analysis of a large nationwide retrospective cohort assessed patients’ characteristics and outcomes associated with nivolumab treatment in clinical practice in France. In both histologies, results suggest similar TTD and OS in real life setting as those observed in phase III trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bristol-Myers Squibb France.
Funding
Bristol-Myers Squibb.
Disclosure
C. Chouaid: Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb. C. Calvet: Full / Part-time employment: Bristol-Myers Squibb. A. Gaudin: Full / Part-time employment: Bristol-Myers Squibb. V. Grumberg: Full / Part-time employment: Bristol-Myers Squibb. R. Jolivel: Honoraria (institution): Bristol-Myers Squibb. B. Jouaneton: Honoraria (institution): Bristol-Myers Squibb. F. Cotté: Full / Part-time employment: Bristol-Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
2036 - Salivary metabolomics for colorectal cancer detection
Presenter: Hiroshi Kuwabara
Session: Poster Display session 3
Resources:
Abstract
1868 - Evaluation and diagnostic potential of plasma biomarkers in bladder cancer
Presenter: Veronika Voronova
Session: Poster Display session 3
Resources:
Abstract
3655 - Liquid biopsy assays using combined circulating tumor cells and circulating tumor DNA in the same patients for the diagnosis of primary lung cancer
Presenter: Yongjoon Suh
Session: Poster Display session 3
Resources:
Abstract
3685 - Peripheral Cytotoxic T Cell Correlates with Tumor Mutational Burden and is Predictive for Progression Free Survival in Advanced Breast Cancer
Presenter: Xiao-ran Liu
Session: Poster Display session 3
Resources:
Abstract
1050 - Splenic Metabolic Activity as Biomarker in Cervical Cancer
Presenter: Emiel De Jaeghere
Session: Poster Display session 3
Resources:
Abstract
1413 - Identification of distinct subtypes revealing prognostic and therapeutic relevance in diffuse type gastric cancer
Presenter: Seon-Kyu Kim
Session: Poster Display session 3
Resources:
Abstract
2140 - Recurrence risk evaluation in stage IB/IIA gastric cancer with TP53 codon 72 polymorphisms
Presenter: Satoshi Nishizuka
Session: Poster Display session 3
Resources:
Abstract
1573 - Identification and validation of a prognostic 4 genes signature for hepatocellular carcinoma: integrated ceRNA network analysis
Presenter: Yongcong Yan
Session: Poster Display session 3
Resources:
Abstract
1196 - Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805)
Presenter: Wenxin Xu
Session: Poster Display session 3
Resources:
Abstract
2657 - Prognostic immunoprofiling of muscle invasive bladder cancer (MIBC) patients in a multicentre setting
Presenter: Katharina Nekolla
Session: Poster Display session 3
Resources:
Abstract